Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer

Jae Yun Lim, Jae Yong Cho, Yong Han Paik, Dong Ki Lee, Sang In Lee, Hyo Jin Park, Se Joon Lee, Kwan Sik Lee, Dong Sup Yoon, Seung Ho Choi

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Background: We conducted a phase II study to assess the efficacy and tolerability of docetaxel and epirubicin as salvage chemotherapy in advanced/metastatic gastric cancer patients with documented progression after 5-fluorouracil/platinum-based combination chemotherapy. Methods: Docetaxel 75 mg/m2 and epirubicin 50 mg/m2 were administered on days 1 and 2, respectively, every 3 weeks. Treatment continued until progression of disease or until a life-threatening adverse event occurred. The primary objectives of this study were to evaluate the safety profile and response rate to this treatment regimen. Results: Thirty-four patients were enrolled in the study. Twenty-six patients had locally advanced or metastatic disease at the time of diagnosis, and 8 patients had recurrent disease after surgical resection of the primary tumor. A total of 157 chemotherapy cycles were administered. Seven (21.8%) patients had a partial response and 12 (37.5%) patients had stable disease. The median time to progression and overall survival were 4.1 and 13.4 months, respectively. Grade III/IV hematologic toxicities included neutropenia in 16 patients (47%) and febrile neutropenia in 8 patients (24%). Nonhematologic toxicities were rare. Conclusion: A combination of chemotherapy with docetaxel and epirubicin showed moderate activity as salvage treatment in advanced/metastatic gastric cancer, especially in patients who had responded to prior chemotherapy.

Original languageEnglish
Pages (from-to)2-8
Number of pages7
Issue number1-2
Publication statusPublished - 2008 Mar

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer'. Together they form a unique fingerprint.

Cite this